Soft-tissue sarcomas are rare tumors arising from mesenchymal tissues. As a heterogeneous group comprising more than 50 types, the development of clinical trials remains challenging. Decision-making for neoadjuvant or adjuvant chemotherapy and radiation therapy is based on the available evidence of contemporary trials and multidisciplinary clinical judgment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jso.26745 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC.
Cancers (Basel)
April 2024
Department of Medical Oncology, Aristotle University of Thessaloniki, Papageorgiou Hospital, 56429 Thessaloniki, Greece.
Non-small cell lung cancer, even when diagnosed in early stages, has been linked with poor survival rates and distant recurrence patterns. Novel therapeutic approaches harnessing the immune system have been implemented in early stages, following the designated steps of advanced NSCLC treatment strategies. Immune-checkpoint inhibitor (ICI) regimens as monotherapy, combinational, or alongside chemotherapy have been intensely investigated as adjuvant, neoadjuvant, and, more recently, perioperative therapeutic strategies, representing pivotal milestones in the evolution of early lung cancer management while holding great potential for the future.
View Article and Find Full Text PDFThe evolution of adjuvant/neoadjuvant trials for resectable localized sarcoma.
J Surg Oncol
January 2022
Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Soft-tissue sarcomas are rare tumors arising from mesenchymal tissues. As a heterogeneous group comprising more than 50 types, the development of clinical trials remains challenging. Decision-making for neoadjuvant or adjuvant chemotherapy and radiation therapy is based on the available evidence of contemporary trials and multidisciplinary clinical judgment.
View Article and Find Full Text PDFDynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy.
Med Res Rev
May 2019
Centre for Biosystems and Genome Network Medicine, Ioannina University, Ioannina, Greece.
Despite remarkable progress in medium-term overall survival benefit in the adjuvant, neoadjuvant and metastatic settings, with multiple recent targeted drug approvals, acquired resistance, late relapse, and cancer-related death rates remain challenging. Integrated technological systems have been developed to overcome these unmet needs. The characterization of structural and functional noncoding genome elements through next-generation sequencing (NGS) systems, Hi-C and CRISPR/Cas9, as well as computational models, allows for whole genome and transcriptome analysis.
View Article and Find Full Text PDFProspective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
Eur J Cancer
July 2017
Service de médecine et biologie du développement et de la reproduction, CHU de Nantes, Nantes, France; INSERM UMR 1064 - ITUN, Nantes, France; Faculté de médecine, Université de Nantes, Nantes, France. Electronic address:
Aim: Women of reproductive age with breast cancer generally receive gonadotoxic chemotherapy. Fertility issues are of great concern for them. However, little is known on ovarian damage during chemotherapy and its evolution during long-term follow-up.
View Article and Find Full Text PDFAromatase inhibitors: past, present and future in breast cancer therapy.
Med Oncol
July 2008
Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Estrogen has been implicated in promoting breast cancer in a majority of women. Endocrine therapy controlling estrogen production has been the guiding principle in treating breast cancer for more than a century. A greater understanding of this disease at a molecular level has led to the development of molecules that inhibit estrogen production by inhibiting the aromatase enzyme, that is the primary source of estrogen in postmenopausal women.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!